BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23674172)

  • 1. Identification of circulating microRNAs in HNF1A-MODY carriers.
    Bonner C; Nyhan KC; Bacon S; Kyithar MP; Schmid J; Concannon CG; Bray IM; Stallings RL; Prehn JH; Byrne MM
    Diabetologia; 2013 Aug; 56(8):1743-51. PubMed ID: 23674172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone morphogenetic protein 3 controls insulin gene expression and is down-regulated in INS-1 cells inducibly expressing a hepatocyte nuclear factor 1A-maturity-onset diabetes of the young mutation.
    Bonner C; Farrelly AM; Concannon CG; Dussmann H; Baquié M; Virard I; Wobser H; Kögel D; Wollheim CB; Rupnik M; Byrne MM; König HG; Prehn JH
    J Biol Chem; 2011 Jul; 286(29):25719-28. PubMed ID: 21628466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential regulation of serum microRNA expression by HNF1β and HNF1α transcription factors.
    Fendler W; Madzio J; Kozinski K; Patel K; Janikiewicz J; Szopa M; Tracz A; Borowiec M; Jarosz-Chobot P; Mysliwiec M; Szadkowska A; Hattersley AT; Ellard S; Malecki MT; Dobrzyn A; Mlynarski W
    Diabetologia; 2016 Jul; 59(7):1463-1473. PubMed ID: 27059371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. INS-1 cells undergoing caspase-dependent apoptosis enhance the regenerative capacity of neighboring cells.
    Bonner C; Bacon S; Concannon CG; Rizvi SR; Baquié M; Farrelly AM; Kilbride SM; Dussmann H; Ward MW; Boulanger CM; Wollheim CB; Graf R; Byrne MM; Prehn JH
    Diabetes; 2010 Nov; 59(11):2799-808. PubMed ID: 20682686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of hepatocyte nuclear factor-1A and -4A on pancreatic stone protein/regenerating protein and C-reactive protein gene expression: implications for maturity-onset diabetes of the young.
    Kyithar MP; Bonner C; Bacon S; Kilbride SM; Schmid J; Graf R; Prehn JH; Byrne MM
    J Transl Med; 2013 Jun; 11():156. PubMed ID: 23803251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating CD36 is reduced in HNF1A-MODY carriers.
    Bacon S; Kyithar MP; Schmid J; Costa Pozza A; Handberg A; Byrne MM
    PLoS One; 2013; 8(9):e74577. PubMed ID: 24069322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating ghrelin level is higher in HNF1A-MODY and GCK-MODY than in polygenic forms of diabetes mellitus.
    Nowak N; Hohendorff J; Solecka I; Szopa M; Skupien J; Kiec-Wilk B; Mlynarski W; Malecki MT
    Endocrine; 2015 Dec; 50(3):643-9. PubMed ID: 25987348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of HNF1A-MODY and HNF4A-MODY in Irish families: phenotypic characteristics and therapeutic implications.
    Kyithar MP; Bacon S; Pannu KK; Rizvi SR; Colclough K; Ellard S; Byrne MM
    Diabetes Metab; 2011 Dec; 37(6):512-9. PubMed ID: 21683639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular background and clinical characteristics of HNF1A MODY in a Polish population.
    Skupien J; Gorczynska-Kosiorz S; Klupa T; Cyganek K; Wanic K; Borowiec M; Sieradzki J; Malecki MT
    Diabetes Metab; 2008 Nov; 34(5):524-8. PubMed ID: 18838325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maturity Onset Diabetes of the Young (MODY) in Tunisia: Low frequencies of GCK and HNF1A mutations.
    Ben Khelifa S; Martinez R; Dandana A; Khochtali I; Ferchichi S; Castaño L
    Gene; 2018 Apr; 651():44-48. PubMed ID: 29408271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-inheritance of HNF1a and GCK mutations in a family with maturity-onset diabetes of the young (MODY): implications for genetic testing.
    López-Garrido MP; Herranz-Antolín S; Alija-Merillas MJ; Giralt P; Escribano J
    Clin Endocrinol (Oxf); 2013 Sep; 79(3):342-7. PubMed ID: 23009393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of HNF1A variants in paediatric diabetes in Norway using functional and clinical investigations to unmask phenotype and monogenic diabetes.
    Svalastoga P; Kaci A; Molnes J; Solheim MH; Johansson BB; Krogvold L; Skrivarhaug T; Valen E; Johansson S; Molven A; Sagen JV; Søfteland E; Bjørkhaug L; Tjora E; Aukrust I; Njølstad PR
    Diabetologia; 2023 Dec; 66(12):2226-2237. PubMed ID: 37798422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multigenerational study on phenotypic consequences of the most common causal variant of HNF1A-MODY.
    Kettunen JLT; Rantala E; Dwivedi OP; Isomaa B; Sarelin L; Kokko P; Hakaste L; Miettinen PJ; Groop LC; Tuomi T
    Diabetologia; 2022 Apr; 65(4):632-643. PubMed ID: 34951657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
    Hohendorff J; Szopa M; Skupien J; Kapusta M; Zapala B; Platek T; Mrozinska S; Parpan T; Glodzik W; Ludwig-Galezowska A; Kiec-Wilk B; Klupa T; Malecki MT
    Endocrine; 2017 Aug; 57(2):272-279. PubMed ID: 28593615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel insights into genetics and clinics of the HNF1A-MODY.
    Valkovicova T; Skopkova M; Stanik J; Gasperikova D
    Endocr Regul; 2019 Apr; 53(2):110-134. PubMed ID: 31517624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin protects against dominant negative-HNF1A-induced apoptosis in INS-1 cells.
    Farrelly AM; Kilbride SM; Bonner C; Prehn JH; Byrne MM
    Apoptosis; 2011 Nov; 16(11):1128-37. PubMed ID: 21874357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A decision algorithm to identify patients with high probability of monogenic diabetes due to HNF1A mutations.
    Szopa M; Klupa T; Kapusta M; Matejko B; Ucieklak D; Glodzik W; Zapala B; Sani CM; Hohendorff J; Malecki MT; Skupien J
    Endocrine; 2019 Apr; 64(1):75-81. PubMed ID: 30778899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life assessment in patients with HNF1A-MODY and GCK-MODY.
    Szopa M; Matejko B; Ucieklak D; Uchman A; Hohendorff J; Mrozińska S; Głodzik W; Zapała B; Płatek T; Solecka I; Sani CM; Małecki MT
    Endocrine; 2019 May; 64(2):246-253. PubMed ID: 30421137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower Circulating miR-122 Level in Patients with HNF1A Variant-Induced Diabetes Compared with Type 2 Diabetes.
    Huang X; Gong S; Ma Y; Cai X; Zhou L; Luo Y; Li M; Liu W; Zhang S; Zhang X; Ren Q; Zhu Y; Zhou X; Zhang R; Chen L; Gao X; Zhang F; Wang Y; Han X; Ji L
    J Diabetes Res; 2018; 2018():7842064. PubMed ID: 30155490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and clinical characteristics of patients with HNF1A gene variations from the German-Austrian DPV database.
    Awa WL; Thon A; Raile K; Grulich-Henn J; Meissner T; Schober E; Holl RW;
    Eur J Endocrinol; 2011 Apr; 164(4):513-20. PubMed ID: 21224407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.